HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
STOK
Stoke Therapeutics, Inc.
STOK lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
STOK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
STOK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
STOK PE Valuation
STOK has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
STOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STOK's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
STOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.77 | -639% |
| Q2 2026 | -$3.34 | -480% |
| Q1 2026 | -$2.81 | -443% |
| Q4 2025 | -$0.12 | +$1.53 |
| Q3 2025 | $0.70 | +$2.81 |
| Q2 2025 | $0.88 | +$3.07 |
| Q1 2025 | $0.82 | +$3.24 |
| Q4 2024 | -$1.65 | +$0.73 |
STOK has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over STOK on profitability, with a higher operating margin.
STOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | +5.9% |
| Q2 2026 | $9.3M | -33% |
| Q1 2026 | $6.2M | -96% |
| Q4 2025 | $1.4M | -94% |
| Q3 2025 | $10.6M | +117% |
| Q2 2025 | $13.8M | +186% |
| Q1 2025 | $158.6M | +3661% |
| Q4 2024 | $22.6M | +707% |
STOK's revenue is recovering but still below its 2025 peak: $11M last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -687% | -282 points |
| Q2 2026 | -702% | -504 points |
| Q1 2026 | -858% | -928 points |
| Q4 2025 | -4382% | -4322 points |
| Q3 2025 | -405% | +208 points |
| Q2 2025 | -198% | +410 points |
| Q1 2025 | 70% | +743 points |
| Q4 2024 | -60% | +996 points |
STOK's operating margin was −687% last quarter, down 282 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over STOK on cash generation, producing positive trailing cash flow while its opponent burns cash.
STOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.5M | -$35M |
| Q2 2026 | -$58.6M | -$33M |
| Q1 2026 | -$60.9M | -146% |
| Q4 2025 | -$30.7M | -$7.5M |
| Q3 2025 | -$30.5M | -$8.8M |
| Q2 2025 | -$25.6M | -$8.1M |
| Q1 2025 | $131.7M | +$156.3M |
| Q4 2024 | -$23.2M | -$2.4M |
STOK has burned cash in almost every quarter: −$216M over the past year, against $52M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over STOK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
STOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +2.3M shares |
| 1 year | +17% | +9.8M shares |
| 3 years | +54% | +24.1M shares |
| 5 years | +86% | +31.6M shares |
| Available history | +108% | +35.5M shares |
STOK has 68M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
STOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.9x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.8x | Net Cash |
STOK has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
STOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 36.1 | Neutral |
STOK's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
STOK PE vs Healthcare Sector
| Metric | STOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STOK has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
STOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.4 | 3.1% above |
| 20 week MA | $28.5 | 8% below |
| 50 week MA | $30.7 | 15% below |
| 100 week MA | $22.9 | 14% above |
| 200 week MA | $16.2 | 61% above |
STOK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
STOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.6 | $58.3 | +119% |
| 2021 | $58.3 | $21.6 | -63% |
| 2022 | $21.6 | $8.30 | -62% |
| 2023 | $8.30 | $5.26 | -37% |
| 2024 | $5.26 | $11.1 | +110% |
| 2025 | $11.1 | $31.9 | +189% |
| 2026 YTD | $31.9 | $26.2 | -18% |
STOK has the edge over HIMS on returns for 2026, with the stronger performance.